Winner PK, Spierings ELH, Yeung PP, et al. - Researchers sought to appraise the onset of efficacy for fremanezumab in chronic migraine by assessing pain-related clinical measures at different time points. In this double-blind phase III study, they randomized 1,130 patients to receive either subcutaneous injections of fremanezumab quarterly (675 mg at baseline, placebo at weeks 4 and 8), fremanezumab monthly (675 mg at baseline, 225 mg at weeks 4 and 8), or placebo at each time point (fremanezumab quarterly, n = 376; fremanezumab monthly, n = 379; or placebo, n = 375). Compared with the placebo group, all fremanezumab group exhibited a reduction in the mean number of monthly headache days of at least moderate severity during the 4-week period after the first dose. The analysis suggests the potential of the early onset of efficacy of fremanezumab for improving patient compliance and clinical outcomes.